Development & Validation of HPLC Method for Analysis of Some Antihypertensive Agents in their Pharmaceutical Dosage Forms

Shalini Pachauri\textsuperscript{a,} Sarvesh Paliwal\textsuperscript{b,} Kona S Srinivas\textsuperscript{a,} Yogendra Singh\textsuperscript{a,} Varun Jain\textsuperscript{a}

\textsuperscript{a} Ranbaxy Research Lab, Gurgaon, Haryana, 122001 India; \textsuperscript{b} Banasthali University, Rajasthan, 301022 India

Abstract:
A simple, precise, fast and gradient, high performance liquid chromatographic (HPLC) method was developed and validated for the determination of Aliskiren, Ramipril, Valsartan and Hydrochlorothiazide in solid dosage forms. The quantitative determination of analyte(s) was performed on a Purosphere Star RP 18e analytical column (250×4.6 mm) with 0.2 \% v/v TEA buffer (pH: 3.0): ACN as mobile phase, at a flow rate of 1.0 mL min\textsuperscript{-1}. Detection was made by extracting PDA spectra at 215 nm respectively. During method validation, parameters such as precision, linearity, stability, Robustness, Ruggedness and specificity were evaluated, which remained within acceptable limits. The method has been successfully applied to assess the assay of solid dosage formulations.

Keywords: Liquid chromatography; Aliskiren; Ramipril; Valsartan; Hydrochlorothiazide; Solid dosage formulations; Validation; simultaneous determination

Introduction:
Hypertension or high blood pressure is a chronic medical condition in which the blood pressure in the arteries is elevated. It is classified as either primary (essential) or secondary. About 90-95 \% of cases are termed "primary hypertension", which refers to high blood pressure for which no medical cause can be found. The remaining 5-10 \% of cases (Secondary hypertension) are caused by another conditions that affect the kidneys, arteries, heart, or endocrine system. Blood pressure is classified based on two types of measurements, the systolic and diastolic blood pressures expressed as a ratio such as '120 over 80' (120/80) mmHg. Systolic blood pressure is the blood pressure in vessels during a heart beat. Diastolic blood pressure is the pressure between heartbeats.

Aliskiren (Figure 1a), a highly potent and selective inhibitor of human renin in vitro, and in vivo; once-daily oral doses of Aliskiren inhibit renin and lower blood pressure in sodium-depleted marmosets and hypertensive human patients. Aliskiren represents the first in a novel class of renin inhibitors with the potential for treatment of hypertension and related cardiovascular diseases. Aliskiren administered both orally or intravenously. Aliskiren is also available as combination therapy with Hydrochlorothiazide.

Ramipril (Figure 1b) is an angiotensin-converting enzyme (ACE) inhibitor, used to treat hypertension and congestive heart failure. ACE inhibitors lower the production of angiotensin II, therefore relaxing arterial muscles while at the same time enlarging the arteries, allowing the heart to pump blood more easily, and increasing blood flow due to more blood being pumped into and through larger passageways. Ramipril is a prodrug and is converted to the active metabolite ramiprilat by liver esterase enzymes.

Valsartan (Figure 1c) is in a class of drugs called angiotensin II receptor antagonists. This medicine works by preventing constriction (narrowing) of blood vessels (veins and arteries). Valsartan is used to treat high blood pressure (hypertension), congestive heart failure and to reduce cardiovascular death in patients. Valsartan is available as tablets for oral administration, containing 40 mg, 80 mg, 160 mg or 320 mg of valsartan. Valsartan may cause hypotension if it is taken with other heart medication.
Hydrochlorothiazide (Figure 1d) is a first line diuretic drug of the thiazide class that acts by inhibiting the kidneys' ability to retain water. This reduces the volume of the blood, decreasing blood return to the heart. Hydrochlorothiazide is used to treat excessive fluid accumulation and swelling (edema) of the body caused by heart failure, cirrhosis, chronic kidney failure, corticosteroid medications, and nephrotic syndrome. The usual adult dose for hypertension is 12.5 to 50 mg once daily. The usual adult dose for treating edema is 25-100 mg once daily or in divided doses. Blood sugar levels can be elevated by hydrochlorothiazide, necessitating adjustment in the doses of medications that are used for treating diabetes.

The safety and efficacy of drug therapy can be ensured using a validated analytical method to assess the quality of pharmaceutical products as it has been considered suitable for their intended purpose, like quantitation of active ingredients (assay).

Since validated methods are applied routinely, some essential aspects must be observed during the technique development to avoid an excessive waste of financial resource. The mobile phase is an important factor to be considered during development of the HPLC method. Thus, solvents that have a low price and extend the column life are generally chosen. Also the choice of column should be such that it should be rugged, easily available; batch variation should be less and can sustain a longer life. Furthermore, the application of the method is relevant because it is fast and determines the range of linearity. The present work reports the development and validation of a method that can be applied for the determination of Aliskiren, Ramipril, Valsartan and Hydrochlorothiazide in individual dosage form and in combination. Furthermore the method has stability indicating capability.

**Experimental:**

**Chemicals & Reagents**

All solvents were of HPLC grade and all reagents were of analytical grade.
Triethylamine, ortho-phosphoric acid and hydrogen peroxide were obtained from SD Fine Chemicals (India). Acetonitrile, Hydrochloric acid, sodium hydroxide was obtained from Rankem (India). Water was purified with Milli-Q Plus, Millipore System (USA). All solvents and solutions were filtered through a membrane filter (Millipore Millex -HV filter units, 0.45 µm pore size; nylon) and degassed before use. All solutions were profiteered before injecting into HPLC system using Millipore milex hydrophilic PTFE unit filter of 0.45 µm pore size.

**Instrumentation and Analytical Conditions**

The HPLC method development and validation procedures was performed on Waters Alliance HPLC system (waters 2695 separation module), equipped with a photo diode array detector (Waters 2996 photo diode array detector). Data integration was performed using Empower-1 software. The analytical column was a normal phase 18e (250*4.6 mm, 5 µm particle size) (PUROSPHERE STAR RP). All analysis was carried out at a temperature of 40±2 °C under gradient conditions. The mobile phase consisted of a mixture of 0.2 % v/v Triethylamine buffer (pH 3.0, adjusted with diluted ortho-phosphoric acid): Acetonitrile. The flow rate was 1.0 mL/min, the volume of injection was 20 µL, all chromatograms were monitored in 200-400 nm range using Photo diode detector and the detection was made by extracting chromatogram at 215 nm in table 1.

**Table 1: Concentration**

| Time | Buffer conc. | ACN conc. |
|------|--------------|-----------|
| 0    | 90           | 10        |
| 4    | 85           | 15        |
| 10   | 30           | 70        |
| 18   | 90           | 10        |
| 25   | 90           | 10        |

**Sample Preparations**

Aliskirene, Ramipril, Valsartan and Hydrochlorothiazide were taken respectively 50 mg (99.7 %), 50 mg (99.8 %) 25 mg (99.8 %) and 25 mg (99.8 %) accurately weighed and transferred to a 50 mL volumetric flask and to this about 3 mL of ACN was added, mixture was sonicated for 5 min and then diluent (ACN:Water 1:1) was added, resulting mixture was sonicated . 5 mL of each solution was diluted to 50 mL with the diluent (Water:ACN 1:1) to get final concentration of 50, 50, 25 and 25 µg mL⁻¹ for Aliskirene Ramipril, Valsartan and Hydrochlorothiazide respectively. Resulting solution was filtered through 0.45µm pore size PTFE filter units before use.

**Method Development**

The chromatographic conditions were adjusted in order to provide a good assay performance. Mobile phase selection was based on peak parameters (tailing) and run time.

**Method Validation:**

The method applied for the determination of Aliskiren, Ramipril, Valsartan and Hydrochlorothiazide in pharmaceuticals was validated according to the International Conference on Harmonisation guidelines for analytical procedures validation. [29]

**Linearity**

The linearity was evaluated by linear regression analysis using the least square regression method. The calibration curve was obtained with fifteen concentrations of standard solution (20-120 % of nominal concentrations with 10 % increment) for the chromatographic method.

**Precision**

Six injections of the standard mixture were analyzed for the determination of system precision. Similarly six solutions of the individual standards were prepared and assayed for the determination of method precision.
Figure 2: shows a typical chromatogram obtained from the analysis of a standard mixture using the proposed method.

**Specificity**
The specificity was determined by analyzing system blank, diluent and different placebos. As shown in this figure, peaks represent Aliskiren (Run Time 10.952 minute and Tailing 1.5), Ramipril (Run Time 11.318 minute and Tailing 1.1), Valsartan (Run Time 12.106 minute and Tailing 1.5) and Hydrochlorothiazide (Run Time 6.458 minute and Tailing 1.2) respectively.
The possible interferences were analyzed by the peak purity, which was calculated using Empower-1 software.
For degradation studies, samples were subjected to acidic, alkaline and oxidative degradation the resulting solutions were analyzed using proposed method.

**Robustness**
For the HPLC method, the robustness was determined by the analysis of the samples under a variety of conditions making small changes in the buffer pH (2.8 and 3.0), in the percentage of mobile phase component±2.0 % (Buffer: ACN), in the flow rate (0.9 and 1.1 mL min⁻¹), in the temperature conditions (35 °C and 45 °C) and by changing the wavelength of detection (210 and 220 nm).

**Stability**
The sample was analyzed for more than 27 hrs at room temperature i.e. at 25 °C and found stable.

**Results and Discussion:**

**Linearity**
The calibration curve of analytes was assessed by plotting concentration versus peak area. The R² values was found to be 0.9993, 0.9927, 0.9997 and 0.9997 for Aliskiren, Ramipril, Valsartan and Hydrochlorothiazide respectively.
The linear range obtained for the procedure applied to formulations by HPLC allows one to assay of active pharmaceutical ingredient containing Aliskiren, Ramipril, Valsartan and Hydrochlorothiazide in individual formulation.

**Precision and accuracy**
The calculated results for accuracy and precision in table 2.

| Parameter          | Aliskiren | Ramipril | Valsartan | Hydrochlorothiazide |
|--------------------|-----------|----------|-----------|---------------------|
| System Precision   | 0.28      | 1.14     | 0.41      | 0.30                |
| Method Precision   | 1.87      | 0.92     | 0.43      | 0.26                |
### Parameter Normal Variation

| Parameter               | Normal | Variation | Aliskiren | Ramipril | Valsartan | Hydrochlorothiazide |
|-------------------------|--------|-----------|-----------|----------|-----------|---------------------|
| pH of buffer (pH unit)  | 3.0    | 2.8       | 0.65      | 1.81     | 0.82      | 1.60                |
|                         | 3.2    | 1.34      | 1.61      | 0.56     | 1.88      |                     |
| Flow rate (mL min⁻¹)    | 1.0    | 0.9       | 1.14      | 1.25     | 1.33      | 0.88                |
|                         | 1.1    | 1.75      | 1.12      | 1.53     | 1.46      |                     |
| Column Temperature (ºC) | 40     | 35        | 1.84      | 1.15     | 0.82      | 1.49                |
|                         | 45     | 1.79      | 1.57      | 0.38     | 1.19      |                     |
| Wavelength (nm)         | 215    | 210       | 0.76      | 1.28     | 1.08      | 0.91                |
|                         | 220    | 1.35      | 1.58      | 1.71     | 1.88      |                     |

### Mobile Phase-

| Parameter               | Aliskiren | Ramipril | Valsartan | Hydrochlorothiazide |
|-------------------------|-----------|----------|-----------|---------------------|
| Mobile Phase (-2 %) (% RSD) | 1.31      | 1.07     | 0.39      | 1.79                |
| Mobile Phase (+2 %) (% RSD)  | 1.54      | 1.70     | 0.65      | 1.42                |

### Specificity
For the proposed HPLC method, no interference from the matrix and excipients was found in the placebo of the tablets. The chromatograms show that peaks are pure, satisfy system suitability criteria and drug not degraded more than 30%.

### Robustness
The HPLC method demonstrated robustness for all evaluated parameters. Robustness of the method for determination of Aliskiren, Ramipril, Valsartan and Hydrochlorothiazide.

### Stability
The drug stability was determined up to 27 hours. The cumulative % RSD value for Aliskiren, Ramipril, Valsartan and Hydrochlorothiazide was found to be 0.9 %, 1.6 %, 1.1% and 1.2 % respectively.

### Conclusion:
The proposed HPLC method enables a fast quantitative determination of Aliskiren, Ramipril, Valsartan and Hydrochlorothiazide in individual formulation or in combinations. It is of practical utility because all the molecules are available in individual formulation and a combination of Aliskiren and Hydrochlorothiazide is available. The application of this method in routine analysis can be justified since easy sample preparation steps are involved with simple reagents and solvents were used experimentally. The validation demonstrated that the procedure is suitable for the intended purpose because the method was considered linear, precise, robust, rugged and specific and can be employed in quality control of pharmaceuticals containing Aliskiren, Ramipril, Valsartan and Hydrochlorothiazide. It is advisable to prepare individual standard solutions in case when single analyte is present in dosage form. As the run time is only 25 min this method is very economical in regular use.
References:

[1] Dieterich H, Kemp C, Vaidyanathan S, and Yeh C (2006) Aliskiren, the first in a new class of orally effective renin inhibitors, has no clinically significant drug interactions with digoxin in healthy volunteers. Clin Pharmacol Ther 79: 64 (PIII-24).

[2] Dieterle W, Corynen S, and Mann J (2004) Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol 58: 433–436.

[3] Dieterle W, Corynen S, Vaidyanathan S, and Mann J (2005) Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther 43: 527–535.

[4] Fisher ND and Hollenberg NK (2005) Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol 16: 592–599.

[5] Garner RC, Barker J, Flavell C, Garner JV, Whattam M, Young GC, Cussans N, Jezequel S, and Leong D (2000) A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts. J Parma Biomed Anal 24: 197–209.

[6] Garner RC (2000) Accelerator mass spectrometry in pharmaceutical research and development—a new ultrasensitive analytical method for isotope measurement. Curr Drug Metab 1: 205–213.

[7] Sevgi Tatar, Serap Saglik Comparison of UV and second derivative spectrophotometric and LC methods for the determination of valsartan in pharmaceutical formulation. Journal of Pharmaceutical and Biomedical Analysis, Volume 30, Issue 2, 5 September 2002, Pages 371-375.

[8] Eric Francotte, Alexander Davatz, Paul Richert Development and validation of chiral high-performance liquid chromatographic methods for the quantitation of valsartan and of the tosylate of valinebenzyl ester Journal of Chromatography B: Biomedical Sciences and Applications, Volume 686, Issue 1, 8 November 1996, Pages 77-83.

[9] M. Rizzo, D. Ventrice, F. Casale, G.F. Caselli, F. Makovec Pharmacokinetic study of a new angiotensin-AT1 antagonist by HPLC. Journal of Pharmaceutical and Biomedical Analysis, Volume 48, Issue 2, 29 September 2008, Pages 422-427.

[10] M. Rizzo, D. Ventrice, F. Monforte, S. Procopio, G. De Sarro, M. Anzini, A. Cappelli, F. Makovec Sensitive SPE–HPLC method to determine a novel angiotensin-AT1 antagonist in biological samples. Journal of Pharmaceutical and Biomedical Analysis, Volume 35, Issue 2, 16 April 2004, Pages 321-3

[11] Warner GT, Perry CM, Ramipril: A review of its use in the prevention of cardiovascular outcomes, Drugs, 62, 2002, 1381-1405. [2] Maurer HH, Kraemer T, Arlt JW, Screening for the detection of angiotensin-converting enzyme inhibitors, their metabolites, and at II receptor antagonists, Ther. Drug Monit., 20, 1998, 706-713.

[12] ICH [Validation of Analytical Procedures: Methodology (Q2R1)], International Conference on Harmonization, Food and Drug Administration, USA, November 1996 and November 2005.

[13] Szepei Gabor., HPLC in pharmaceutical Analysis, Volume I, (1990), 101-173.

[14] Jeffery G.H., Bassett J., Vogels textbook of Quantitative Chemical Analysis, 5th edition, (1991), 217-235.

[15] Willard Hobart. H., Merritt L.L., Dean John.A., Instrumental Methods of Analysis, 7th edition, CBS Publishers, 580-610.

[16] Sharma B.K., Instrumental Methods of Chemical Analysis, 20th edition, GOEL Publishing House, (2001), 54-83.

[17] Yu Joseph. G., Kruszynska Yolanta. T., and Mulfor Mlm. I. , Diabetes, (1999), 48(12), 2414-2421.

[18] Gandhimathi M., Anandakumar K., Cheriyan A., and Ravi T.K., Indian Journal of Pharmaceutical Science., 2003., 65(6).,530-531.

[19] www.pharmaarticles.net/exclusive/technical/basics-principles-of-hptlc.html

[20] The United States Pharmacopoeia. 29th ed. Rockwell, MD: The United States Pharmacopeial Convention, Inc; 2006.

[21] The British Pharmacopoeia. London: British Pharmacopoeial Commission; 2005.

[22] Shah NJ, Suhagia BN, Shah RR, Patel NM. Development and validation of a HPTLC method for the simultaneous estimation of irbesartan and hydrochlorothiazide in tablet dosage form. Indian J Pharm Sci 2007;69:240-3

[23] Frampton JE, Peters DH (March 1995). "Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure" [24] Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet (8875): 821–8. October 1993.